8 completed, 2 active not recruiting, 2 recruiting, 2 terminated. 16 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 16 | Completed 8, Active not recruiting 2, Recruiting 2, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
Follow Heart Failure With Preserved Ejection Fraction: new trials by email Literature Review of Heart Failure With Preserved Ejection Fraction trials Research Report on Heart Failure With Preserved Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity Maridebart cafraglutide, Placebo - Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction | Phase 3 | Recruiting | Amgen | 5056 | 2025-06-25 | 2026-10-29 |
| A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction Low calorie meal replacement plan, Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy, Transthoracic echocardiography - Heart Failure With Preserved Ejection Fraction, Heart Failure, Diastolic | Phase 2 / Phase 3 | Completed | University of Leicester | 66 | 2023-12-05 | 2026-07-22 |
| The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction Metformin - Heart Failure With Preserved Ejection Fraction, Diabete Type 2 | Phase 2 / Phase 3 | Unknown | October University for Modern Sciences and Arts | 80 | 2023-11-01 | 2023-10-12 |
| Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation Enavogliflozin, Placebo - Tricuspid Regurgitation, Heart Failure With Preserved Ejection Fraction | Phase 3 | Active not recruiting | Asan Medical Center | 541 | 2023-10-25 | 2025-12-29 |
| A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension Associated With Left Heart Failure Pulmonary arterial denervation, Guideline-directed medical therapy (GDMT) for heart failure - Pulmonary Hypertension, Heart Failure With Reduced Ejection Fraction | Phase 3 | Active not recruiting | Pulnovo Medical (Wuxi) Co., Ltd. | 264 | 2023-08-14 | 2026-07-21 |
| Dapagliflozin With or Without Spironolactone for HFpEF Dapagliflozin, Spironolactone + Dapagliflozin - Heart Failure With Preserved Ejection Fraction | Phase 2 / Phase 3 | Completed | Universidade do Porto | 108 | 2022-09-15 | 2025-08-17 |
| Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF) Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo - Iron-deficiency, Heart Failure With Preserved Ejection Fraction | Phase 2 / Phase 3 | Completed | Massachusetts General Hospital | 65 | 2021-11-26 | 2026-09-04 |
| Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% AZD4831, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 2 / Phase 3 | Completed | AstraZeneca | 711 | 2021-06-30 | 2025-08-27 |
| Study of Sacubitril/ValsarTan on MyocardIal OxygenatioN and Fibrosis in Heart Failure With Preserved Ejection Fraction Sacubitril-Valsartan - Heart Failure With Preserved Ejection Fraction | Phase 3 | Withdrawn | Flinders University | 2020-02-01 | 2021-08-30 | |
| Spironolactone in the Treatment of Heart Failure Experimental: Spironolactone, Placebo Comparator - Heart Failure with Mid-range Ejection Fraction, Heart Failure with Preserved Ejection Fraction | Phase 3 | Terminated | Charite University, Berlin, Germany | 743 | 2018-11-01 | 2025-03-28 |
| Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. Dapagliflozin, Placebo - Heart Failure With Preserved Ejection Fraction | Phase 3 | Completed | AstraZeneca | 6263 | 2018-08-27 | 2023-07-11 |
| Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction Spironolactone, Standard care - Heart Failure With Preserved Ejection Fraction | Phase 3 | Recruiting | Uppsala University | 2000 | 2017-11-23 | 2024-10-22 |
| A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients sacubitril/valsartan, Enalapril, Valsartan - Heart Failure With Preserved Ejection Fraction | Phase 3 | Completed | Novartis Pharmaceuticals | 2572 | 2017-08-22 | 2021-10-11 |
| Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction Oral treprostinil, Placebo - Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction | Phase 3 | Terminated | United Therapeutics | 84 | 2017-08-15 | 2020-11-10 |
| Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction LCZ696, Valsartan - Heart Failure With Preserved Ejection Fraction | Phase 3 | Completed | Novartis Pharmaceuticals | 4822 | 2014-07-18 | 2020-09-29 |
| Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure Enalapril, placebo - Heart Failure With Preserved Ejection Fraction, Heart Failure, Congestive | Phase 3 | Completed | Wake Forest University | 71 | 2003-07-01 | 2017-11-06 |
Heart Failure (7) · Cardiovascular Diseases (2) · Diabetes Mellitus, Type 2 (2) · Heart Failure, Diastolic (2) · Hypertension, Pulmonary (2) · Obesity (2) · Anemia, Iron-Deficiency (1) · Hypertension (1) · Iron Deficiencies (1) · Tricuspid Valve Insufficiency (1) · Vascular Diseases (1)
Heart Diseases (9) · Cardiovascular Diseases (8) · Nutritional and Metabolic Diseases (4) · Metabolic Diseases (3) · Body Weight (2) · Diabetes Mellitus (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Lung Diseases (2) · Nutrition Disorders (2) · Overnutrition (2) · Overweight (2) · Pathological Conditions, Signs and Symptoms (2) · Respiratory Tract Diseases (2) · Signs and Symptoms (2)
Valsartan (3) · sacubitril and valsartan sodium hydrate drug combination (3) · Enalapril (2) · Spironolactone (2) · dapagliflozin (2) · AZD4831 (1) · Diagnostic Imaging (1) · Diet (1) · Echocardiography (1) · Electrocardiography (1) · Enavogliflozin (1) · Hematologic Tests (1) · Metformin (1) · Positron-Emission Tomography (1) · Saline Solution (1)
AstraZeneca (2) · Novartis Pharmaceuticals (2) · Amgen (1) · Asan Medical Center (1) · Charite University, Berlin, Germany (1) · Flinders University (1) · Massachusetts General Hospital (1) · October University for Modern Sciences and Arts (1) · Pulnovo Medical (Wuxi) Co., Ltd. (1) · United Therapeutics (1) · Universidade do Porto (1) · University of Leicester (1) · Uppsala University (1) · Wake Forest University (1)
United States (8) · Netherlands (6) · Belgium (5) · Brazil (5) · Bulgaria (5) · Canada (5) · Czechia (5) · France (5) · Hungary (5) · Argentina (4) · Austria (4) · China (4) · Denmark (4) · Germany (4) · Japan (4)
Adelino Leite-Moreira, MD, PhD (1) · Bertram Pitt (1) · Burkert Pieske, Prof. MD (1) · Carmine De Pasquale, Assoc Prof (1) · Dalane W Kitzman, MD (1) · David Kaye, Professor (1) · Gerry P McCann, MD (1) · Greg Lewis, MD (1) · Lars H Lund, MD, PhD (1) · Majo Joseph, Doctor (1)
PMID 42669134, PMID 25415957, PMID 28662936, PMID 29890892, PMID 29980595, PMID 31081589, PMID 31302043, PMID 31475794, PMID 31726194, PMID 31736337, PMID 31736342, PMID 31806129, PMID 32192799, PMID 32241619, PMID 32731928, PMID 32845715, PMID 33189633, PMID 33714741, PMID 33727901, PMID 33839075, PMID 33866828, PMID 33888245, PMID 33998278, PMID 34097449, PMID 34392331, PMID 34693515, PMID 34783839, PMID 34796742, PMID 34807713, PMID 34918855, PMID 35241246, PMID 35483796, PMID 35603665, PMID 35603667, PMID 35717169, PMID 35895867, PMID 36027570, PMID 36029465, PMID 36029467, PMID 36041668, PMID 36041669, PMID 36041912, PMID 36050227, PMID 36100197, PMID 36114137, PMID 36189985, PMID 36190011, PMID 36326604, PMID 36372069, PMID 36522606
2016 (1), 2018 (1), R01HL151841 (1), U01HL134679 (1), U01HL134694 (1)